Thrombosis
News
Ticagrelor monotherapy tops DAPT for high-risk PCI patients
SAN FRANCISCO – TWILIGHT findings support move to shorter DAPT.
Clinical
Apixaban prevents clots with cancer
Does apixaban therapy decrease venous thromboembolism (VTE) in ambulatory patients with cancer at intermediate to high risk who are starting...
Clinical
Reversal agents for direct-acting oral anticoagulants
DOACs are increasingly prescribed for anticoagulation, thanks to its multiple advantages.
News
Older IBD patients are most at risk of postdischarge VTE
Readmission for venous thromboembolism in patients with inflammatory bowel diseases most often occurs within 60 days of discharge.
Clinical
Use of a CDSS increases safe outpatient management of low-risk PE patients
Does the use of an electronic clinical decision support system (CDSS) increase the number of low-risk patients with acute pulmonary embolism (PE)...
Clinical
Standardized communication may prevent anticoagulant adverse drug events
What information is needed on discharge to reduce anticoagulant adverse drug events (ADEs)?
News
POP AGE shakes up DAPT in elderly
PARIS – Clopidogrel hailed as P2Y12 inhibitor of choice in older patients with non-ST-elevation ACS.
Clinical
Anticoagulant therapy for AFib in patients with end-stage renal disease
Apixaban may be safer than warfarin for patients who have ESRD and who plan for anticoagulation because of AFib.
News
Post-TAVR anticoagulation alone fails to cut stroke risk in AFib
By contrast, antiplatelet therapy linked to reduced risk of stroke, whether or not oral anticoagulation was used in this PARTNER II substudy.
Clinical
Shorter vs. longer DAPT following coronary stent placement
Is 6 months of dual antiplatelet therapy (DAPT) therapy noninferior to 12 months, following ST-elevation myocardial infarction (STEMI) with...